Background: Whether advances in identification and management of atrial fibrillation and atrial flutter (collectively, AF) have led to improved outcomes is unclear. We sought to study trends in clinical outcomes selected as quality indicators for nonvalvular AF in Canada.

Methods: We identified hospitalized patients with a first diagnosis of nonvalvular AF between April 2006 and March 2015, in all of Canada except Quebec. We assessed trends in 1-year incidence of stroke/systemic embolism (SSE), major bleeding, and initial heart failure (HF) hospitalization.

Results: The cohort included 466,476 patients. The median age was 77 years (interquartile range, 68-84 years), 46% were female, and 68% had a ongestive Heart Failure, ypertension, ge (≥75 years), iabetes, troke/Transient Ischemic Attack, ascular Disease, ge (65-74 years), ex (Female) (CHADS-VASc) score > 3. Within 1 year of discharge, 3.5% were hospitalized for stroke or SSE, 1.6% for major bleeding, and 8.6% for new HF. Over the study period, the crude rate of SSE declined from 3.6% to 3.3% ( = 0.002), whereas the rates of hospitalization for new HF and for major bleeding did not significantly change. After adjustment for CHADS-VASc score, the yearly rates of incident SSE (risk ratio, 0.99; 95% confidence interval [CI], 0.98-0.99;  = 0.002) and HF (risk ratio, 0.99; 95% CI, 0.99-1.00;  = 0.001) declined ≤ 1% absolute, whereas major bleeding remained unchanged (risk ratio, 1.00; 95% CI, 0.99-1.00;  = 0.28).

Conclusions: Among hospitalized patients with nonvalvular AF in Canada, the rate of SSE and new HF decreased modestly over a 10-year period, with no significant change in major bleeding. Efforts to study process-based quality indicators, with increased focus on HF prevention, are needed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134946PMC
http://dx.doi.org/10.1016/j.cjco.2021.01.003DOI Listing

Publication Analysis

Top Keywords

major bleeding
24
quality indicators
12
heart failure
12
risk ratio
12
outcomes selected
8
atrial fibrillation
8
hospitalized patients
8
chads-vasc score
8
rate sse
8
 = 0002
8

Similar Publications

Does patient blood management represent good value for money?

Best Pract Res Clin Anaesthesiol

December 2023

Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Australia; Department of Clinical Haematology, Monash Health, Melbourne, Australia. Electronic address:

Patient blood management is the umbrella term for a suite of initiatives designed to optimise blood product usage, minimise transfusion needs, and ensure appropriate and evidence-based transfusion practices. In this review we summarise published economic evaluations of patient blood management to determine whether they represent good value for money. We identified 54 economic evaluations of patient blood management, the majority of which had positive cost-effectiveness conclusions.

View Article and Find Full Text PDF

Intra-operative tranexamic acid: A standard of care?

Best Pract Res Clin Anaesthesiol

December 2023

Division of Hematology, Departments of Medicine, and Laboratory Medicine and Pathobiology, St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada. Electronic address:

Peri-operative bleeding is a major cause of morbidity and mortality in patients undergoing surgery. Tranexamic acid, an antifibrinolytic agent, is effective for prevention and treatment of bleeding in a variety of different surgical populations. This review summarizes the evidence supporting the use of tranexamic acid in major surgical settings including cardiac surgery, obstetrics, orthopedic surgery, and non-cardiac surgery.

View Article and Find Full Text PDF

Background: Patients with end-stage kidney disease (ESKD) have high rates of gastrointestinal bleeding due to several risk factors including platelet dysfunction, comorbid illness, and use of antiplatelet medications. Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding and are recommended for high-risk patients such as those prescribed dual antiplatelet therapy (DAPT). Whether inappropriate duration of DAPT therapy and/or lack of appropriate PPI use contribute to the known elevated risk of gastrointestinal bleeding in hemodialysis patients is not known.

View Article and Find Full Text PDF

Lipoprotein(a) [Lp(a)] is a well-established cardiovascular disease (CVD) risk factor with elevated Lp(a) levels contributing to a higher incidence of atherosclerotic CVD (ASCVD). However, no Lp(a)-specific interventions are currently available in the primary CVD prevention in individuals with elevated Lp(a) levels. RNA-based therapies targeting Lp(a) are under investigation in phase III clinical trials.

View Article and Find Full Text PDF

Background: Type 2 diabetes mellitus (T2DM) patients with small-diameter stents (SDS), that are equal to or less than 2.5 mm in diameter, face increased risks of restenosis and complications. This study aimed to evaluate the 1-year follow-up to assess the rate of major adverse cardiac events (MACE) and bleeding risk between ticagrelor and clopidogrel in T2DM patients after SDS implantation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!